Differentiating thyroiditis from Graves disease without RAIU
How to differentiate between thyroiditis and Graves’ disease in the absence of facility of RAIU. Does Trab have any role.
When a radioactive iodine uptake (RAIU) scan is unavailable, differentiate Graves disease from thyroiditis by combining clinical clues, laboratory tests, and thyroid ultrasound with color Doppler. A positive TSH‑receptor antibody (TRAb/TSI) strongly supports Graves disease; a negative result makes Graves less likely but does not completely rule it out. Ultrasound findings are also discriminative: Graves typically shows a diffusely enlarged gland with marked hypervascularity (“thyroid inferno”), whereas thyroiditis (subacute, painless, or postpartum) shows normal or reduced flow, and subacute thyroiditis may have focal hypoechoic, tender areas. Laboratory patterns help further: both conditions have elevated FT4/FT3 and suppressed TSH, but Graves often has a higher FT3:FT4 ratio and a sustained course, while thyroiditis shows a transient thyrotoxic phase with a low/absent uptake physiology, followed by hypothyroidism and recovery. Inflammatory markers (elevated ESR/CRP) and neck pain point toward subacute thyroiditis; lack of pain, presence of ophthalmopathy or dermopathy favor Graves. Clinical exam findings such as a bruit over a non‑tender goiter support Graves, whereas tenderness supports thyroiditis. Practical algorithm: if TRAb is positive and Doppler shows hypervascularity, treat as Graves (antithyroid drugs, beta‑blocker, consider definitive therapy). If TRAb is negative, the gland is tender, ESR/CRP are elevated, and Doppler flow is low, manage as thyroiditis (NSAIDs or steroids for pain, beta‑blocker for symptoms, no antithyroid drugs). A short trial of beta‑blocker alone with repeat labs in 4–6 weeks can also clarify the diagnosis, as thyroiditis will improve spontaneously while Graves persists. Trab (thionamide therapy) is used for Graves disease but has no role in treating thyroiditis.